Industry
Pharmaceuticals
Developers of branded and generic drugs. Value creation rests on R&D pipelines, patent lifecycles, regulatory approvals and pricing power versus payers.
Total Companies
1 300
1 247 stocks
| Company | Last Price | Price Change | Market Cap | ||
|---|---|---|---|---|---|
|
|
|
Eli Lilly and Co
LLY
|
$1 015.75 |
+7.1%
|
$959.7B |
|
|
|
Johnson & Johnson
JNJ
|
$230.42 |
+4.1%
|
$555B |
|
|
|
Roche Holding AG
ROG
|
CHf324.9 |
+4.1%
|
$338.3B |
|
|
|
AstraZeneca PLC
AZN
|
GBX13 766 |
+2%
|
$290.8B |
|
|
|
Novartis AG
NOVN
|
CHf116.8 |
+2.7%
|
$288.3B |
|
|
|
Merck & Co Inc
MRK
|
$113.45 |
+1.9%
|
$280.2B |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr299.2 |
-0.3%
|
$209.3B |
|
|
|
Pfizer Inc
PFE
|
$25.96 |
+1.1%
|
$147.7B |
|
|
|
Bristol-Myers Squibb Co
BMY
|
$56.39 |
+0.4%
|
$115.1B |
1 242 results hidden
Create a free account to unlock additional access and upgrade to see all results
Create Free Account
